cynata therapeutics Archives | Page 9 of 9

Cynata Therapeutics is a regenerative medicine company, listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).

UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007.

Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of human embryonic stem cell (hESC) derivation. [Read more…]

Cynata’s Stem Cell Manufacturing Platform to Allow for Scalability of Harvard’s Modified Stem Cells

While methods for treating cancer have improved over the past decade, there remain limited techniques for addressing aggressive cancers, including those that cannot be surgically removed due to location or type. Cancers such as glioblastoma, the most common and aggressive type of brain tumour in adult humans, continue to produce high fatality rates. In addition, chemotherapy remains a widespread technique for killing or stopping cancer progression, despite its extremely harmful side effects. For this reason, cell therapies are now being explored for their potential to act as targeted cancer killing agents. [Read more…]

Cynata Introduces a Scalable Mesenchymal Stem Cell (MSC) Manufacturing Platform

Cynata Therapeutics and Harvard to Target Cancer with Toxin-Secreting Stem Cells

Cynata’s Stem Cell Manufacturing Platform to Allow for Scalability of Harvard’s Modified Stem Cells

BioInformant's World-Class Clients